PREFER looks at how and when it is best to perform and include patient-preference in decision making during the drug life cycle.
They include patient stakeholders at every level of the project.
The end-result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.
Mats G. Hansson, Professor of Biomedical Ethics and Director of the Centre for Research Ethics & Bioethics (CRB) at Uppsala University
